Showing posts with label EPO. Show all posts
Showing posts with label EPO. Show all posts

Wednesday, June 03, 2015

Neuromics' Neuronal Cultures in Action

Drug Discovery and Tox Assay Publications

Our Primary Human, Rat and Mouse Neurons are widely used and frequently cited in publications. Here's a pub hot of the presses referencing use of our e18 Rat Cortical Neurons to study the 
EPO-like cytoprotective effects cultures of these cells: James L. Miller, Timothy J. Church, Dmitri Leonoudakis, Karen Lariosa-Willingham, Normand L. Frigon, Connie S, Tettenborn, Jeffrey R. Spencer, and Juha Punnonen. Discovery and Characterization of Nonpeptidyl Agonists of The Tissue-Protective Erythropoietin Receptor. Molecular Pharmacology. May 27, 2015 mol.115.098400

...Cells were isolated from micro-surgically dissected embryonic day 18 rat cortices that were obtained from Neuromics (Edina, MN), and cultures were prepared according to the supplier's protocol.

Image: Neuromics' Cortical Neurons @ Day 6 in Culture.

I will new and unique applications for our neurons, astroglia and neural progenitors here. If you have questions, do not hesitate to contact me @ 612-801-1007 or pshuster@neuromics.com. Pete Shuster, CEO and Owner, Neuromics

Saturday, February 21, 2015

i-Fect Delivers siRNA in vitro and in vivo

Gene Expression Analysis for Studying Stroke

We have posted over 35 publications that reference use of our i-Fect Transfection Kit to deliver siRNA, miRNA and shRNA in vitro and in vivo. Results documented in these publications prove that this kit is both non-toxic and delivers ultra-high transfection efficiency.

i-Fect Data Example


Figure. The effects of HDAC2 siRNA Infusion into the CeA of P rats on voluntary ethanol consumption as measured by the two-bottle free choice paradigm. Monitoring the voluntary ethanol consumption of alcohol-preferring (P) rats via the two bottle free choice paradigm following infusion of vehicle or histone deacetylase isoform 2 (HDAC2) siRNA into the central amygdala (CeA) demonstrates that high HDAC2 levels may mediate the high alcohol drinking behaviors of P rats. P rats were given access to water and 7% ethanol followed by water and 9% ethanol. On the sixth day of ethanol access P rats received infusion of vehicle or HDAC2 siRNA and consumption of water and 9% ethanol were monitored for sevnfusion. Total fluid intake did not significantly differ between the groups. Values are represented as the mean ± SEM of the ethanol consumption (g / kg / day) and total fluid intake (mL) plotted daily for n=6 rats per treatment group. *Significantly different between the groups.SACHIN MOONAT. The Role of Amygdaloid Chromatin and Synaptic Remodeling in Anxiety and Alcoholism. THESIS Submitted as partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate College of the University of Illinois at Chicago, 2014.

Here's yet another recent publication highlighting use of i-Fect:

In this study data suggest the protective effects of EPO on NUV injuries are highly associated with the increase of p-Cx43, which improves GJIC to reduce neurotoxic substances: Ziyi Zhoua, Xiaobai Weib, Jun Xiang, Junpeng Gao, Lixin Wang, Jinsong You, Yefeng Cai , Dingfang Caid. Protection of erythropoietin against ischemic neurovascular unit injuries through the effects of connexin43. Biochemical and Biophysical Research Communications. doi:10.1016/j.bbrc.2015.02...The strands were incubated at 90°C for 5 min and then at 37°C for 1 h. SiRNA was prepared immediately before administration by mixing the RNA solution (1 μg/μl in annealing buffer) with the transfection reagent i-Fect (v/v: 1/3; Neuromics, Edina, MN, USA) to a final siRNA ...

Highlights
•EPO has protective effects on ischemic NVU injuries.
•EPO up-regulates phosphorylation of Cx43, not total Cx43.
•EPO's protective effects on NUV injuries are p-Cx43-GJIC dependent.